DeepUll Appoints Richard Ivey to its Board of Directors

Diagnostics industry veteran with forty years’ experience to support DeepUll in its continued development of its early sepsis identification system BARCELONA, Spain – October 4 2021 – DeepUll, a medical diagnostics company developing culture-free, affordable diagnostic solutions for the early identification of sepsis and other acute infections, announces today that it has appointed Richard (“Rick”) Ivey as a non-executive director. With four decades of senior leadership experience in the diagnostics…

Inbiomotion’s MAF Test ® selects breast cancer patients benefitting from adjuvant clodronate, significantly improving their overall survival

• Level 1 evidence from the MAF Test ®analyses of the NSABP-B34 landmark clinical trial confirmed clinical utility of the MAF Test ® for selection of early-stage breast cancer patients that benefit from adjuvant clodronate treatment to prevent metastasis. • Data published in Journal of National Cancer Institute, Cancer Spectrum. • MAF negative status of patients who were treated with clodronate in the adjuvant setting was predictive of significantly improved…

PEPTOMYC SL Announces Treatment of First Patient with its Lead Compound OMO-103 in a Phase I/II Clinical Trial

Barcelona, Thursday 6th May 2021 Peptomyc, a Spanish clinical stage biotech company spin-off of the Vall d’Hebron Institute of Oncology (VHIO) and the Catalan Institute of Research and Advanced Studies (ICREA) in Barcelona, reported that on Tuesday 4th May the first patient has been dosed with OMO-103, its anti-MYC lead compound, in a Phase I/II study, under the supervision of Dr. Elena Garralda at the Hospital Universitari Vall d’Hebron in…

INBRAIN Neuroelectronics raises over €14M Series A led by Alta Life Sciences, Asabys Partners and CDTI to develop intelligent graphene-based neuroelectronic therapies for brain related disorders

Barcelona, March 26th , 2021 INBRAIN Neuroelectronics is a spin-off company from Graphene Flaship partners’ the Catalan Institute of Nanoscience and Nanotechnology (ICN2) and ICREA, established in 2019 in the intersection between Medtech, DeepTech and Digital Health. INBRAIN has the mission to decode brain signals into medical solutions by developing intelligent neuroelectronic therapies based on graphene technology for application in patients with Epilepsy, Parkinson’s and other brain related disorders. In…